CINXE.COM
World Pharma Today e-Newsletter - Week 16 - April 2017
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN" "http://www.w3.org/TR/REC-html40/loose.dtd"> <html><head></head><title>World Pharma Today e-Newsletter - Week 16 - April 2017</title><body> <div align="center"> <table width="700" border="0"> <tbody> <tr> <td height="21"><div style="font-family: Arial, Helvetica, sans-serif; font-size: 12px;" align="center">If you are not able to view this e-mail properly, please <a href="http://www.worldpharmatoday.com/E-Newsletter/2017/week16/" target="_blank">click here</a> to view it online</div></td> </tr> </tbody> </table> <table width="700" border="1" align="center"> <tr><td> <title></title><table width="100%" border="0" align="center" cellpadding="10px;"><tr> <td width="30%"><a href="http://www.worldpharmatoday.com/" target="_blank"><img src="http://worldpharmatoday.com/images/WPTLogo.jpg" alt="World Pharma Today Maqazine" width="145" height="65" border="0"></a></td> <td width="70%"><table width="80%" border="0" align="right"><tbody><tr><td width="50"><a href="https://www.linkedin.com/company/world-pharma-today?trk=biz-companies-cym" target="_blank"><img src="http://www.worldpharmatoday.com/images/article/Weekly_newsletter/comman_images/worldpharmatoday_linkedin.png" alt="World Pharma Today Linkedin Page"></a></td> <td width="50"><a href="https://www.facebook.com/WorldPharmaToday/" target="_blank"><img src="http://www.worldpharmatoday.com/images/article/Weekly_newsletter/comman_images/worldpharmatoday_facebook.jpg" alt="World Pharma Today Facebook Page"></a></td> <td width="50"><a href="https://twitter.com/worldpharma2day" target="_blank"><img src="http://www.worldpharmatoday.com/images/article/Weekly_newsletter/comman_images/worldpharmatoday_twitter.png" alt="World Pharma Today Twitter Page"></a></td> <td width="145"><strong style="font-family:Arial, Helvetica, sans-serif; font-size:16px">Weekly Newsletter</strong></td> </tr></tbody></table></td> </tr></table> <table width="100%" bgcolor="#0077BB" border="0"> <tbody> <tr> <td style="padding-top: 5px; padding-bottom: 5px;"><div style="text-transform: uppercase; color: #fff;" align="center"><span style="color: #ffffff; font-family: Arial,Helvetica,sans-serif; font-size: 14px; text-transform: uppercase;"><a style="color: #ffffff;" href="http://www.worldpharmatoday.com/subscribe-here-for-world-pharma-today-magazine" target="_blank">Click here</a> to subscribe to our Magazine</span></div></td> </tr> </tbody> </table> <table width="100%" border="0"> <tbody> <tr> <td style="padding-top: 10px; padding-bottom: 10px; text-align: center;"><a href="http://www.worldpharmatoday.com/banners/click17 " title="CPHI China 2017" target="_blank"><a href="http://www.worldpharmatoday.com/banners/click17 " title="The Health Industry Summit (tHIS) 2017" target="_blank"><img src="http://www.worldpharmatoday.com/images/article/Weekly_newsletter/week_16/The_Health_Industry_Summit_2017.gif" alt="The Health Industry Summit (tHIS) 2017" width="468" height="60" border="0" /></a></td> </tr> </tbody> </table> <table width="100%" height="28px" border="0" align="center" cellpadding="0px" bgcolor="#0077BB"><tbody><tr><td style="width: 5%;"></td> <td style="line-height: 0px; width: 5%;"><img src="http://www.worldpharmatoday.com/images/article/Weekly_newsletter/comman_images/7.png" alt="" width="" height=""></td> <td style="color: #ffffff; font-size: 24px; font-family: Arial,Helvetica,sans-serif; width: 85%;">Top Latest Press Releases</td> <td style="width: 5%;"></td> </tr></tbody></table><table width="100%" border="0" align="center"><tr><td width="5%"></td> <td width="42%"><div align="center"><a href="http://www.worldpharmatoday.com/News/medical-fair-thailand-2017-reflects-the-bullish-growth-of-the-medical-industry-in-the-region" title="Medical fair thailand 2017" target="_blank"><img src="http://www.worldpharmatoday.com/images/article/Weekly_newsletter/week_16/Medical_fair_Thailand_2017.jpg" alt="Medical fair thailand 2017 " width="280" height="200"></a></div></td> <td width="6%"></td> <td width="42%"><p style="font-size: 16px; font-family: Arial,Helvetica,sans-serif; font-weight: bold">Medical fair thailand 2017 reflects the bullish growth of the Medical industry in the region</p> <p style="font-family: Arial,Helvetica,sans-serif; font-size: 12px; line-height: 18px; text-align: left; color:#666">This year edition of MEDICAL FAIR THAILAND is set to be its biggest yet with more than 700 international exhibitors expected. 17 national and country pavilions will present more than 5,000 state-of-the-art medical and healthcare products...</p> <table width="120px" cellspacing="0" cellpadding="0" border="0" align="left" style="margin-bottom: 15px;"> <tbody><tr> <td style="background-color:#07b; font-family: Arial,Helvetica,sans-serif; color: rgb(138, 255, 255); font-size: 12px; text-align: center; padding: 8px; font-weight: bold; text-transform: uppercase;"><a href="http://www.worldpharmatoday.com/News/medical-fair-thailand-2017-reflects-the-bullish-growth-of-the-medical-industry-in-the-region" title="Medical fair thailand 2017" target="_blank" style="color: rgb(255, 255, 255); text-decoration: none;">READ MORE</a></td> </tr></tbody></table></td> <td width="5%"></td> </tr></table> <table width="100%" border="0" align="center"> <tr> <td><hr></td> </tr> </table> <table width="100%" border="0" align="center"><tr><td width="5%"></td> <td width="42%"><p style="font-size: 16px; font-family: Arial,Helvetica,sans-serif; font-weight: bold"><span style="color: #000000; font-size: 16px; font-family: arial;">Inovio Ebola Vaccine Demonstrates Robust Immune Responses with Favorable Safety Profile in Clinical Trial </span></p> <p style="font-family: Arial,Helvetica,sans-serif; font-size: 12px; line-height: 18px; text-align: left; color:#666">Inovio Pharmaceuticals, Inc. announced preliminary results from the expanded stage of its phase I study, EBOV-001. The expanded study examined different regimens of its Ebola DNA vaccine...</p> <table width="120" cellspacing="0" cellpadding="0" border="0" align="left" style="margin-bottom: 15px;"> <tbody><tr> <td style="background-color:#07b; font-family: Arial,Helvetica,sans-serif; color: rgb(138, 255, 255); font-size: 12px; text-align: center; padding: 8px; font-weight: bold; text-transform: uppercase;"><a href="http://www.worldpharmatoday.com/Clinical-Trials/inovio-ebola-vaccine-demonstrates-robust-immune-responses-with-favorable-safety-profile-in-expanded-clinical-trial" title="Inovio Ebola Vaccine Demonstrates Responses with Favorable Safety in Clinical Trial" target="_blank" style="color: rgb(255, 255, 255); text-decoration: none;">READ MORE</a></td> </tr></tbody></table></td> <td width="6%"></td> <td width="42%"><p style="font-size: 16px; font-family: Arial,Helvetica,sans-serif; font-weight: bold;">LDC and SOTIO Enter License and Collaboration Agreement for First-in-class Cancer Metabolism Program </p> <p style="font-family: Arial,Helvetica,sans-serif; font-size: 12px; line-height: 18px; text-align: left; color:#666">The Lead Discovery Center GmbH Max Planck Innovation GmbH (MI) and SOTIO a.s. have signed a collaboration and license agreement providing SOTIO with exclusive rights to an oncology program addressing a novel target in tumor metabolism.</p> <table width="120px" cellspacing="0" cellpadding="0" border="0" align="left" style="margin-bottom: 15px;"> <tbody><tr> <td style="background-color:#07b; font-family: Arial,Helvetica,sans-serif; color: rgb(138, 255, 255); font-size: 12px; text-align: center; padding: 8px; font-weight: bold; text-transform: uppercase;"><a href="http://www.worldpharmatoday.com/Drug-Research/ldc-and-sotio-enter-license-and-collaboration-agreement-for-first-in-class-cancer-metabolism-program" title="LDC and SOTIO Enter Collaboration Agreement for First-in-class Cancer Metabolism Program" target="_blank" style="color: rgb(255, 255, 255); text-decoration: none;">READ MORE</a></td> </tr></tbody></table></td> <td width="5%"></td> </tr></table> <table width="100%" height="28px" border="0" align="center" cellpadding="0px" bgcolor="#0077BB"> <tbody> <tr> <td style="width: 5%;"></td> <td style="line-height: 0px; width: 5%;"><span style="line-height: 0px;"><img src="http://www.worldpharmatoday.com/images/article/Weekly_newsletter/comman_images/6.png" alt="" width="" height=""></span></td> <td style="color: #ffffff; font-size: 24px; font-family: Arial,Helvetica,sans-serif; width: 85%;"><span style="color: #fff; font-size: 24px; font-family: Arial, Helvetica, sans-serif;">Articles</span></td> <td style="width: 5%;"></td> </tr> </tbody> </table> <table width="100%" border="0" align="center"> <tr> <td width="5%"></td> <td width="42%"><div align="center"><a href="http://www.worldpharmatoday.com/Press-Releases/eyevensys-receives-french-regulatory-approval-to-advance-eyecet-platform" title="Eyevensys receives French regulatory approval to advance EyeCET platform" target="_blank"><img src="http://www.worldpharmatoday.com/images/article/Weekly_newsletter/week_16/Eyevensis_Eye_Gene_Therapy.jpg" alt="Eyevensys receives French regulatory approval to advance EyeCET platform" width="280" height="200"></a></div></td> <td width="6%"></td> <td width="42%"><p style="font-size: 16px; font-family: Arial,Helvetica,sans-serif; font-weight: bold">Eyevensys receives French regulatory approval to advance EyeCET platform</p> <p style="font-family: Arial,Helvetica,sans-serif; font-size: 12px; line-height: 18px; text-align: left; color:#666">Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables the safe, local, sustained production of therapeutic proteins in the eye to address ophthalmic diseases.</p> <table width="120px" cellspacing="0" cellpadding="0" border="0" align="left" style="margin-bottom: 15px;"> <tbody> <tr> <td style="background-color:#07b; font-family: Arial,Helvetica,sans-serif; color: rgb(138, 255, 255); font-size: 12px; text-align: center; padding: 8px; font-weight: bold; text-transform: uppercase;"><a href="http://www.worldpharmatoday.com/Press-Releases/eyevensys-receives-french-regulatory-approval-to-advance-eyecet-platform" title="Eyevensys receives French regulatory approval to advance EyeCET platform" target="_blank" style="color: rgb(255, 255, 255); text-decoration: none;">READ MORE</a></td> </tr> </tbody> </table></td> <td width="5%"></td> </tr> </table> <table width="100%" border="0" align="center"> <tr> <td><hr></td> </tr> </table> <table width="100%" border="0" align="center"> <tr> <td width="5%"></td> <td width="42%"><p style="font-size: 16px; font-family: Arial,Helvetica,sans-serif; font-weight: bold"><span style="color: #000000; font-size: 16px; font-family: arial;">Imprimis Pharmaceuticals acquires license to patented formulation for dry eye disease</span></p> <p style="font-family: Arial,Helvetica,sans-serif; font-size: 12px; line-height: 18px; text-align: left; color:#666">Imprimis Pharmaceuticals Inc , an ophthalmology-focused pharmaceutical company, announced that it has entered into an licensing agreement for the exclusive worldwide rights to Klarity...</p> <table width="120" cellspacing="0" cellpadding="0" border="0" align="left" style="margin-bottom: 15px;"> <tbody> <tr> <td style="background-color:#07b; font-family: Arial,Helvetica,sans-serif; color: rgb(138, 255, 255); font-size: 12px; text-align: center; padding: 8px; font-weight: bold; text-transform: uppercase;"><a href="http://www.worldpharmatoday.com/Industry-Reports/imprimis-pharmaceuticals-acquires-license-to-patented-formulation-for-dry-eye-disease" title="Imprimis Pharmaceuticals acquires license to patented formulation for dry eye disease" target="_blank" style="color: rgb(255, 255, 255); text-decoration: none;">READ MORE</a></td> </tr> </tbody> </table></td> <td width="6%"></td> <td width="42%"><p style="font-size: 16px; font-family: Arial,Helvetica,sans-serif; font-weight: bold;">Neurocrine Announces FDA Approval of INGREZZA TM Capsules </p> <p style="font-family: Arial,Helvetica,sans-serif; font-size: 12px; line-height: 18px; text-align: left; color:#666">Neurocrine Biosciences, Inc. announced that the U.S. FDA has approved INGREZZATM (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD).INGREZZA, a novel, selective vesicular monoamine transporter...</p> <table width="120px" cellspacing="0" cellpadding="0" border="0" align="left" style="margin-bottom: 15px;"> <tbody> <tr> <td style="background-color:#07b; font-family: Arial,Helvetica,sans-serif; color: rgb(138, 255, 255); font-size: 12px; text-align: center; padding: 8px; font-weight: bold; text-transform: uppercase;"><a href="http://www.worldpharmatoday.com/News/neurocrine-announces-fda-approval-of-ingrezza-tm-capsules" title="Neurocrine Announces FDA Approval of INGREZZA TM Capsules" target="_blank" style="color: rgb(255, 255, 255); text-decoration: none;">READ MORE</a></td> </tr> </tbody> </table></td> <td width="5%"></td> </tr> </table> <table width="100%" border="0" align="center" bgcolor="#0077BB"><tr><td width="5%"> </td> <td style="color:#FFF; font-family:Arial, Helvetica, sans-serif; font-size:12px" width="42%"><p style="font-family: Arial,Helvetica,sans-serif; font-size: 12px; color: #fff; margin-bottom: 5px; text-align: left;"><span style="font-weight: bold; font-size: 14px;">For Advertising Queries:</span><br> <br> <span style="font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#FFF;"> Please e-mail : <a style="color: #fff;" href="mailto:kathryn@worldpharmatoday.com?subject=Reference%20World%20Pharma%20Today%20-%20weekly%20newsletter" target="_blank">kathryn@worldpharmatoday.com </a><br> or <br> call to: + 91 88268 49084 <br> <br> If you like to receive our latest <strong>Media Pack 2017</strong> / <strong>Editorial Calender</strong> please <a style="color: #ffffff;" href="mailto:kathryn@worldpharmatoday.com?subject=Reference%20World%20Pharma%20Today%20-%20weekly%20newsletter&body=I%20will%20be%20interested%20to%20in%20receiving%20the%20Mediapack%20for%202017%20and%20my%20details%20are%20as%20mentioned%20below.%20%0A%0D%0A%20Name%20%3A%0D%0A%20Company%20Name%20%3A%0D%0A%20Phone%20No%20%3A%0D%0A%20" target="_blank">click here</a></span><br></td> <td width="6%"> </td> <td style="color:#FFF; font-family:Arial, Helvetica, sans-serif; font-size:12px" width="42%"><p align="left"><span style="font-family: Arial,Helvetica,sans-serif; font-size: 12px; color: #fff; margin-bottom: 5px; text-align: left; line-height: 20px;">For the latest visit: <a style="color: #ffffff; text-decoration: none;" title="World Pharma Today" href="http://www.worldpharmatoday.com/" target="_blank"><strong>www.worldpharmatoday.com</strong></a></span></p><p align="left"><a href="http://www.worldpharmatoday.com/" target="_blank"><img src="http://worldpharmatoday.com/images/WPTLogo.jpg" alt="World Pharma Today" width="145" height="65" border="0"></a></p></td> <td width="5%"> </td> </tr></table></td> </tr></table> </div></body></html>